Best Asian Stocks To Own For 2015

Best Asian Stocks To Own For 2015: Seattle Genetics Inc.(SGEN)

Seattle Genetics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases in the United States. Its lead product, SGN-35 is in pivotal trial stage used for the treatment of patients with relapsed or refractory hodgkin lymphoma. The company?s other product candidates in various stages of clinical trials include SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; dacetuzumab (SGN-40), a humanized anti-CD40 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc .; Daiichi Sankyo Co., Ltd.; Genentech, Inc.; GlaxoSmithKline LLC; Millennium; and PSMA Development Company LLC. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc.; and Genmab A/S. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.

Advisors' Opinion:

• [By Rich Bieglmeier]

  [Related -Seattle Genetics, Inc. (SGEN), Takeda Report Encouraging Data From ADCETRIS Study]

  Let's take a look at what $2 billion in ADCETRIS sales could mean for the stock price and where SGEN shares would need to trade to become a low-end large cap stock.

• [By Sean Williams]

  These might not be household names in the U.S., but they do brandish global licensing partnerships with companies that might be more familiar to you. Takeda, for example, has licensing agreements! in place with Orexigen Therapeutics (NASDAQ: OREX  ) , which recently filed a New Drug Application for its chronic weight management (i.e., anti-obesity) pill, Contrave, in the U.S. Takeda owns the right to Contrave outside of North America. In addition, Takeda is a collaborative partner of antibody-drug conjugate developer Seattle Genetics (NASDAQ: SGEN  ) with regard to FDA-approved Hodgkin lymphoma drug Adcetris. 

source from Top Stocks For 2015:http://www.topstocksblog.com/best-asian-stocks-to-own-for-2015.html